NASDAQ:SNCA Seneca Biopharma (SNCA) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free SNCA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$6.68▼$6.9050-Day Range$1.39▼$10.2552-Week Range$0.50▼$2.67Volume12,654 shsAverage Volume3.78 million shsMarket Capitalization$116.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Seneca Biopharma alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Seneca Biopharma Stock (NASDAQ:SNCA)Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. SNCA Stock News HeadlinesMarch 2, 2024 | gurufocus.comLeading BioSciences Inc, Seneca Biopharma, Inc. - M&A Call TranscriptMarch 2, 2024 | gurufocus.comLeading BioSciences, Inc., Seneca Biopharma, Inc. - M&A Call TranscriptMay 13, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.December 16, 2023 | morningstar.comSeneca Foods Corp Class AApril 30, 2023 | usnews.comWest Seneca West Senior High SchoolApril 19, 2023 | usnews.comSeneca High SchoolFebruary 16, 2023 | usatoday.com'This is a tragedy': Giraffe dies after getting caught in enclosure gate at New York zooSee More Headlines Receive SNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seneca Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SNCA CUSIPN/A CIKN/A Webwww.senecabio.com Phone(301) 366-4960FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,350,000.00 Net Margins-230.34% Pretax MarginN/A Return on Equity-122.20% Return on Assets-110.61% Debt Debt-to-Equity RatioN/A Current Ratio14.96 Quick Ratio14.96 Sales & Book Value Annual Sales$10,000.00 Price / Sales11,605.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book5.05Miscellaneous Outstanding Shares17,296,000Free FloatN/AMarket Cap$116.06 million OptionableNot Optionable Beta1.83 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Kenneth C. Carter (Age 61)Exec. Chairman Comp: $492.5kMr. Dane R. Saglio (Age 63)Principal Exec. & Accounting Officer Comp: $435.75kDr. Karl Y. Johe (Age 61)Co-Founder Dr. David P. Recker FACR (Age 63)M.D., FACP, Chief Medical Officer Key CompetitorsCardiol TherapeuticsNASDAQ:CRDLMolecular PartnersNASDAQ:MOLNVaxartNASDAQ:VXRTScilexNASDAQ:SCLXDBV TechnologiesNASDAQ:DBVTView All Competitors SNCA Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Seneca Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seneca Biopharma investors own include OpGen (OPGN), Sorrento Therapeutics (SRNE), AIM ImmunoTech (AIM), DURECT (DRRX), Nabriva Therapeutics (NBRV), OPKO Health (OPK), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Fulcrum Therapeutics (FULC) and iBio (IBIO). This page (NASDAQ:SNCA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
